These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 31805989)

  • 1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
    Danto SI; Shojaee N; Singh RSP; Li C; Gilbert SA; Manukyan Z; Kilty I
    Arthritis Res Ther; 2019 Dec; 21(1):269. PubMed ID: 31805989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Cohen S; Beebe JS; Chindalore V; Guan S; Hassan-Zahraee M; Saxena M; Xi L; Hyde C; Koride S; Levin R; Lubaczewski S; Salganik M; Sloan A; Stevens E; Peeva E; Vincent MS; Martin DA; Chu M
    Arthritis Res Ther; 2024 Jun; 26(1):117. PubMed ID: 38845046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.
    Peeva E; Hodge MR; Kieras E; Vazquez ML; Goteti K; Tarabar SG; Alvey CW; Banfield C
    Br J Clin Pharmacol; 2018 Aug; 84(8):1776-1788. PubMed ID: 29672897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects.
    Bhattacharya I; Tarabar S; Liang Y; Pradhan V; Owens J; Oemar B
    Clin Ther; 2016 Jun; 38(6):1401-1416. PubMed ID: 27085586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
    Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
    Mohamed MF; Camp HS; Jiang P; Padley RJ; Asatryan A; Othman AA
    Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies.
    Fuertig R; Goettel M; Herich L; Hoefler J; Wiebe ST; Sharma V
    CNS Drugs; 2023 Dec; 37(12):1081-1097. PubMed ID: 38019355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
    Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
    Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants.
    Lim CN; Kantaridis C; Huyghe I; Gorman D; Berasi S; Sonnenberg GE
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00813. PubMed ID: 34369667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
    Fan Y; Zhang X; Zhang Q; Zheng L; Zhou R; Sun C; Wang X; Song K; He Z; Wang H; Zhang Q; Hu W
    Clin Pharmacokinet; 2024 Mar; 63(3):293-302. PubMed ID: 38198010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis.
    Zhang L; Zhang W; Xu Y; Dong L; Sun Y; Jia Y; Li Z; Chen B; Hou J; Zhang J
    Adv Ther; 2024 Jul; 41(7):2953-2965. PubMed ID: 38833140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
    Bundrant L; Hunt TL; Banks P; Gopinathan S; Boehm KA; Kassler-Taub K; Tyle P; Wilson A; Warner C; Wason S
    Clin Ther; 2021 Jun; 43(6):1029-1050. PubMed ID: 34108079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.
    Guérard N; Morand O; Dingemanse J
    Orphanet J Rare Dis; 2017 Jan; 12(1):9. PubMed ID: 28088251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study.
    Singh RSP; Pradhan V; Roberts ES; Scaramozza M; Kieras E; Gale JD; Peeva E; Vincent MS; Banerjee A; Fensome A; Dowty ME; Winkle P; Tehlirian C
    Clin Transl Sci; 2021 Mar; 14(2):671-682. PubMed ID: 33290616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects.
    Banfield C; Rudin D; Bhattacharya I; Goteti K; Li G; Hassan-Zahraee M; Brown LS; Hung KE; Pawlak S; Lepsy C
    Br J Clin Pharmacol; 2020 Apr; 86(4):812-824. PubMed ID: 31758576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial.
    Liu X; Zhang R; Li R; Wu Q; Pan C; Yu X; Liu Y; Wang B; Yu S
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0107523. PubMed ID: 37971243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
    Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
    Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses.
    Yang Y; Yu L; Sheng Z; Lin H; Weng Z; Song W; Cao B; Zhao Y; Gao Y; Ni S; Wang H; Ma T; Huang L; Sun C; Li J
    Front Pharmacol; 2024; 15():1327008. PubMed ID: 38741586
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
    Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
    Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.